ClinicalTrials.gg
DrugBiologicalRead study by study

Ipilimumab clinical trials

Also written Yervoy, BMS-734016 and MDX-010.

studies test it
521
open now
83
in phase 3
55
first study started
2001
ClinicalTrials.gov finds 993 studies for Ipilimumab. How that becomes 521 hereChecked on ClinicalTrials.gov

Every study that search finds has been read, apart from the 2 newest, to see whether and how it gives Ipilimumab. Its counts are asked again every night. How drug pages count

  1. 993Found by its intervention search · See all 993 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 862 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −25
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. −1New since the last reading, not read yet
  4. +1Give it under a name that search misses: a biosimilar’s code or a misspelling
  5. 968Give Ipilimumab to participants
  6. −99Observe patients on it, or give it outside a trial
  7. −6Use it as a tool: an imaging tracer or a test of drug response
  8. −27Compare another treatment with it
  9. −315Give it beside what is tested
  10. 521Test it: the count on this site

Get an email when these change. Save the Ipilimumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
25 Mar 2011 · YERVOY · BLA 125377 (FDA, Drugs@FDA)
European Union
13 Jul 2011 · Yervoy · EMEA/H/C/002213 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ipilimumab
391
Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
58
MDX-CTLA4
50
monoclonal antibody CTLA-4
10
Ipilimumab Injection
4

Brand

Yervoy
214

Development codes

BMS-734016
121
MDX-010
99
MDX-CTLA-4
10
MDX-101
3
NSC 732442
2

In one entry with another drug

Given together, or one or the other

Nivolumab and Ipilimumab
6
Nivolumab + Ipilimumab
5
Nivolumab & Ipilimumab
4
Nivolumab plus Ipilimumab
4
nivolumab, ipilimumab
2
Ipilimumab & Sintilimab
2
Opdivo and Yervoy
2
ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
2

Biosimilars

CS1002
2

Studies by the year they started

520 studies that test it; most in 2017 (61); 1 more planned to start later

Studies that test Ipilimumab, by start year
YearStudies
20012
20025
20037
20046
20055
20066
20072
20083
20099
20108
201114
201229
201323
201420
201524
201640
201761
201850
201953
202031
202129
202223
202310
202415
202511
202634

By phase

A phase 1/2 study counts in both.

Early Phase 1
7
Phase 1
154
Phase 2
353
Phase 3
55
Phase 4
6
No phase
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 96 · Other 425

Bristol-Myers Squibb (86) · National Cancer Institute (NCI) (48) · M.D. Anderson Cancer Center (29) · Memorial Sloan Kettering Cancer Center (15) · The Netherlands Cancer Institute (15) · Dana-Farber Cancer Institute (12) · H. Lee Moffitt Cancer Center and Research Institute (11) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (9)

Often tested with

Tested in the same studies.

Nivolumab (320) · Cabozantinib (19) · Pembrolizumab (18) · Sintilimab (12) · Ipilimumab/Nivolumab Regimen (12) · Relatlimab (11) · Paclitaxel (10) · Cisplatin (9)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 7 phase 3 studies under way

Ipilimumab is the comparator. A study of two new drugs counts under both.

New treatments tested with it · 8 most studied

New when their studies opened, with Ipilimumab beside them; studies of each.

Reaching primary completion within a year · 51, 1 in phase 3

Studies that test Ipilimumab, phase 3 first.

Studies

Open first, then newest update. How each study uses Ipilimumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 521

See all 521 studies that test Ipilimumab →

Behind its US label · 10 — the studies the FDA label of YERVOY describes

From the Clinical Studies section of YERVOY (2026-08), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 67 — no other medicine in its arm

Showing 20 of 67. See all 67 →

Tested with established drugs · 41 — they are given beside it

Showing 20 of 41. See all 41 →

Tested in a combination · 412 — another drug in the study is under test too

Showing 20 of 412. See all 412 →

Beside an established treatment under test · 72 — an approved drug, surgery or radiation is what the study tests

Tested with Ipilimumab: Nivolumab 20 · Radiation 17 · Surgery or a procedure 16 · cabozantinib 4 · pembrolizumab 3 · Trabectedin 2 · A device 2 · PM 01183 2

Showing 20 of 72. See all 72 →

Beside a new treatment under test · 229 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with Ipilimumab: Nivolumab 14 · cemiplimab 5 · tilsotolimod 4 · pepinemab 3 · clostridium butyricum miyairi 588 strain 3 · vopratelimab 3 · lirilumab 3 · pembrolizumab 3

Showing 20 of 229. See all 229 →

Beside supportive care · 11 — a supportive treatment or test is studied
One option of several · 3 — a test or a strategy chooses among drugs
Given beside what is tested · 1 — usual care or a partner of the new treatment
As the comparator · 27 — what is tested is compared with Ipilimumab

Showing 20 of 27. See all 27 →

Observed · 99 — patients on it are followed, or it is given outside a trial

Showing 20 of 99. See all 99 →

As a tool · 6 — an imaging tracer or a test of drug response

Codes

What other systems call Ipilimumab · ClinicalTrials.gg INT006640

  • MeSH (NLM) D000074324IpilimumabConfirmed ClinicalTrials.gov, Wikidata
  • UNII (FDA) 6T8C155666IPILIMUMABConfirmed FDA, Wikidata
  • RxNorm 1094833Confirmed FDA, Wikidata
  • Wikidata Q2459042ipilimumabConfirmed FDA, Wikidata
  • NCI Thesaurus C2654IpilimumabOne source FDA
  • DrugBank DB06186One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion